Gilead Sciences Inc. (GILD)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
78.17-1.60 (-2.01%)
At close: 4:00 PM EDT
People also watch:
CELGBIIBAMGNREGNFB
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open79.65
Prev Close79.77
Bid78.02 x 200
Ask78.13 x 200
Day's Range77.63 - 79.70
52wk Range77.63 - 113.31
1y Target EstN/A
Market Cap103.16B
P/E Ratio (ttm)6.86
Beta0.99
Volume14,748,608
Avg Vol (3m)10,240,462
Dividend & Yield1.88 (2.36%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • 24/7 Wall St.11 hours ago

    Gilead, Ceasars in Monday’s 52-Week Low Club

    August 29, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Monday’s session. NYSE advancers led decliners by about 7 to 3 and Nasdaq advancers ...

  • TheStreet.com13 hours ago

    Gilead Sciences (GILD) Stock Down, Piper Jaffray 'Doubts' HIV Competitors

    Piper Jaffray said in a note Monday that Gilead Sciences (GILD) likely won't be impacted by GlaxoSmithKline's (GSK) potential new two-drug HIV regimen.

  • Barrons.com14 hours ago

    Gilead Sciences: Don't Expect Perfection

    As if Gilead Sciences (GILD) didn't have enough to worry about with competition in hepatitis C, now the Wall Street Journal is reporting that GlaxoSmithKline (GSK) is attempting to upend the HIV market too. Piper Jaffray's Joshua Schimmer and team don't seem to worried: We have had a number of incoming questions regarding the WSJ article highlighting a potential 2-drug HIV regimen based on GSK's dolutegravir. The costs of HIV resistance are very high, whereas the advantage of a 2-drug regimen over a 3-drug regimen (when both are 1-pill/once daily regimens anyways) is minimal.